文献速递糖尿病

口服葡萄糖耐量试验中循环microRNA动态变化支持其作为囊性纤维化相关糖尿病诊疗标志物

Dynamic changes in circulating microRNAs during oral glucose tolerance testing support their potential as diagnostic and monitoring biomarkers in cystic fibrosis-related diabetes.
PubMed 文献 · Diabetologia · 2026-01-07

研究纳入93例丹麦成人囊性纤维化患者,按糖耐量状态分组,在OGTT基线、10、30、60和180分钟采血,先对12例进行血清microRNA测序筛选候选分子,再用锁定核酸逆转录定量PCR在全队列验证。基线时miR-34a-5p、miR-122-5p、miR-885-3和miR-885-5p存在差异表达,另有12个microRNA对摄糖的反应性变化存在差异;其中8个经PCR验证,miR-34a-5p、miR-122-5p与miR-223-3p进入深入评估。

要点

  • miR-34a-5p与miR-122-5p在不确定糖耐量和CFRD基线升高,并与肝损伤标志物升高相关
  • miR-223-3p在OGTT中差异表达,模式随糖耐量状态而异
  • 过表达miR-122-5p或miR-223-3p增加葡萄糖刺激的胰岛素分泌,过表达miR-34a-5p降低分泌细胞活力

核心结论

  • MiR-34a-5p与miR-122-5p有潜力作为CFRD发生和肝损伤的生物标志物
  • MiR-122-5p与miR-223-3p可能通过提高β细胞分泌能力减缓CFRD发生,miR-34a-5p可能通过降低细胞活力促进CFRD发展
  • 作者提出循环microRNA可作为CF并发症的生物标志物,并参与代谢器官与内分泌胰腺之间的复杂对话

研究设计与样本

  • 研究为横断面设计,队列为93例丹麦成人囊性纤维化患者,分属正常糖耐量、不确定糖耐量、糖耐量受损和CFRD四类
  • 在OGTT基线、10分钟、30分钟、60分钟和180分钟采样
  • 对12例(每类3例)的基线和60分钟样本进行全血清microRNA测序,锁定16个候选microRNA,用锁定核酸逆转录定量PCR在全队列各时间点验证,并选3个microRNA深入评估其对胰岛素分泌的影响

主要发现

  • 基线有4个microRNA差异表达:miR-34a-5p、miR-122-5p、miR-885-3和miR-885-5p
  • 有12个microRNA对摄糖的反应性表达变化存在差异,其中8个经锁定核酸逆转录定量PCR验证
  • miR-34a-5p与miR-122-5p在不确定糖耐量和CFRD基线升高,并与肝损伤标志物升高相关
  • miR-223-3p在OGTT中差异表达,且模式随糖耐量状态不同
  • 在胰岛素分泌细胞中过表达miR-122-5p或miR-223-3p后葡萄糖刺激的胰岛素分泌增加,过表达miR-34a-5p后细胞活力下降

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: MicroRNAs are potential predictors and mediators of metabolic disease. Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in cystic fibrosis (CF). Here we aimed to investigate serum microRNAs in individuals with CF and differing glucose tolerance status. Specifically, we hypothesised that the circulating microRNA profile varies depending on glucose tolerance status and can change rapidly in response to a glucose challenge in individuals with CF. METHODS: We studied a cohort of 93 adult Danish participants with CF from four glucose tolerance categories: normal glucose tolerance, indeterminate glucose tolerance, impaired glucose tolerance and CFRD. In a cross-sectional design we sampled during an OGTT at baseline, 10 min, 30 min, 60 min and 180 min. A total serum microRNA sequencing was performed using baseline and 60 min samples from 12 selected individuals, three from each category. We identified 16 candidate microRNAs, and these were further investigated in the full cohort at all OGTT timepoints using a locked nucleic acid reverse transcription quantitative PCR assay. Three microRNAs were selected for in-depth assessment including impact on insulin secretion. RESULTS: We identified four microRNAs differentially expressed at baseline (miR-34a-5p, miR-122-5p, miR-885-3 and miR-885-5p) and 12 with differential expression changes in response to glucose ingestion. Locked nucleic acid reverse transcription quantitative PCR assay validated the results of eight of these microRNAs and miR-34a-5p, miR-122-5p and miR-223-3p were selected for in-depth assessment. MiR-34a-5p and miR-122-5p were elevated at baseline in indeterminate glucose tolerance and CFRD and were associated with elevated liver damage markers. MiR-223-3p was differentially expressed during the OGTT, with different patterns depending on glucose tolerance state. Glucose-stimulated insulin secretion was increased after overexpression of miR-122-5p or miR-223-3p and cell viability was decreased after overexpression of miR-34a-5p in insulin-secreting cells. CONCLUSIONS/INTERPRETATION: MiR-34a-5p and miR-122-5p show potential as biomarkers for CFRD development and liver damage. MiR-122-5p and miR-223-3p could mitigate CFRD development by increasing the secretory capacity of the beta cells while miR-34a-5p might propagate CFRD development by reducing cell viability. We propose that circulating microRNAs can serve as biomarkers for CF complications. We further advocate that circulating microRNAs can play a part in the intricate crosstalk between metabolic organs and the endocrine pancreas in health and disease.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Westholm E, Karagiannopoulos A, Nielsen BU, et al. Dynamic changes in circulating microRNAs during oral glucose tolerance testing support their potential as diagnostic and monitoring biomarkers in cystic fibrosis-related diabetes. Diabetologia. 2026. PMID: 41498931. doi:10.1007/s00125-025-06645-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。